company background image
ACW logo

Actinogen Medical CHIA:ACW Stock Report

Last Price

AU$0.025

Market Cap

AU$73.8m

7D

-7.4%

1Y

13.6%

Updated

24 Dec, 2024

Data

Company Financials +

Actinogen Medical Limited

CHIA:ACW Stock Report

Market Cap: AU$73.8m

ACW Stock Overview

A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. More details

ACW fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Actinogen Medical Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Actinogen Medical
Historical stock prices
Current Share PriceAU$0.025
52 Week HighAU$0.099
52 Week LowAU$0.02
Beta1.26
1 Month Change0%
3 Month Change8.70%
1 Year Change13.64%
3 Year Change-81.48%
5 Year Change-28.57%
Change since IPO-51.92%

Recent News & Updates

Recent updates

Shareholder Returns

ACWAU BiotechsAU Market
7D-7.4%1.1%-1.0%
1Y13.6%4.6%8.5%

Return vs Industry: ACW exceeded the Australian Biotechs industry which returned 3.7% over the past year.

Return vs Market: ACW exceeded the Australian Market which returned 8.2% over the past year.

Price Volatility

Is ACW's price volatile compared to industry and market?
ACW volatility
ACW Average Weekly Movement9.3%
Biotechs Industry Average Movement10.0%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market3.1%

Stable Share Price: ACW has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: ACW's weekly volatility has decreased from 21% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999n/aSteve Gourlayactinogen.com.au

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.

Actinogen Medical Limited Fundamentals Summary

How do Actinogen Medical's earnings and revenue compare to its market cap?
ACW fundamental statistics
Market capAU$73.76m
Earnings (TTM)-AU$13.04m
Revenue (TTM)AU$9.93m

7.4x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACW income statement (TTM)
RevenueAU$9.93m
Cost of RevenueAU$0
Gross ProfitAU$9.93m
Other ExpensesAU$22.98m
Earnings-AU$13.04m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0042
Gross Margin100.00%
Net Profit Margin-131.34%
Debt/Equity Ratio0%

How did ACW perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 14:23
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Actinogen Medical Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tara SperanzaBell Potter
Pooya HemamiEdison Investment Research